Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Grass Pollen Allergy - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
78 pages
Liver Cirrhosis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
149 pages
Dementia - Pipeline Review, H1 2020
US$ 2,000.00
... . The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
469 pages
Thalassemia - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
198 pages
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2020
US$ 2,000.00
... Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
106 pages
Periodontitis - Pipeline Review, H1 2020
US$ 2,000.00
... And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
58 pages
Restenosis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Restenosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
62 pages
Seborrhea - Pipeline Review, H1 2020
US$ 2,000.00
... pipeline guide Seborrhea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development ...
February 2020
50 pages
Batten Disease - Pipeline Review, H1 2020
US$ 2,000.00
... . The Batten Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Batten Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
92 pages
Activin Receptor Type 1 - Pipeline Review, H1 2020
US$ 3,500.00
... releases. The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
70 pages
Cryptococcosis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Cryptococcosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptococcosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
58 pages
Gonorrhea - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
114 pages
Myocarditis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
48 pages
Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020
US$ 2,000.00
... pipeline guide Proliferative Vitreoretinopathy (PVR) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology), complete with analysis by stage of development ...
February 2020
37 pages
Pulmonary Embolism - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
59 pages
Leiomyosarcoma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
557 pages
Anal Cancer - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
525 pages
Fibrosarcoma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
120 pages
Optic Neuropathy - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
70 pages
Synovial Sarcoma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
359 pages
Becker Muscular Dystrophy - Pipeline Review, H1 2020
US$ 2,000.00
... . The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
75 pages
Meniere Disease - Pipeline Review, H1 2020
US$ 2,000.00
... . The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development ...
February 2020
49 pages
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2020
US$ 2,000.00
... The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under ...
February 2020
75 pages
Primary Immune Deficiency (PID) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
125 pages
Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
623 pages
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2020
US$ 2,000.00
... . The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
156 pages
Complex Regional Pain Syndrome - Pipeline Review, H1 2020
US$ 2,000.00
... . The Complex Regional Pain Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Complex Regional Pain Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development ...
February 2020
60 pages
Crigler-Najjar Syndrome - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
38 pages
Familial Adenomatous Polyposis - Pipeline Review, H1 2020
US$ 2,000.00
... . The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
69 pages
Osteogenesis Imperfecta - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
63 pages
Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H1 2020
US$ 2,000.00
... pipeline guide Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders), complete with analysis by stage of development ...
February 2020
44 pages
Coccidioidomycosis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
76 pages
Contrast Induced Nephropathy - Pipeline Review, H1 2020
US$ 2,000.00
... Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
45 pages
Osteomyelitis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
49 pages
Ragweed Pollen Allergy - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Ragweed Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Ragweed Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
35 pages
Bone Marrow Transplant Rejection - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
751 pages
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
78 pages
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
880 pages
Pressure Ulcers - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
32 pages
Alpha L-Iduronidase - Pipeline Review, H1 2020
US$ 3,500.00
Alpha L-Iduronidase - Pipeline Review, H1 2020 SUMMARY Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are develo...
February 2020
64 pages
Apoptosis Regulator BAX - Pipeline Review, H1 2020
US$ 3,500.00
Apoptosis Regulator BAX - Pipeline Review, H1 2020 SUMMARY Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 7 molecules. Out of which approximatel...
February 2020
47 pages
Bromodomain Containing Protein 2 - Pipeline Review, H1 2020
US$ 3,500.00
Bromodomain Containing Protein 2 - Pipeline Review, H1 2020 SUMMARY Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is...
February 2020
70 pages
Bromodomain Containing Protein 3 - Pipeline Review, H1 2020
US$ 3,500.00
Bromodomain Containing Protein 3 - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'Bromodomain Containing Protein 3 - Pipeline Review, H1 2020'; Bromodomain Containing P...
February 2020
69 pages
Cell Division Protein FtsZ - Pipeline Review, H1 2020
US$ 3,500.00
Cell Division Protein FtsZ - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2020'; Cell Division Protein FtsZ (f...
February 2020
34 pages
Dystrophin - Pipeline Review, H1 2020
US$ 3,500.00
Dystrophin - Pipeline Review, H1 2020 SUMMARY Dystrophin (DMD) pipeline Target constitutes close to 49 molecules. Out of which approximately 43 molecules are developed by companies and remaining by...
February 2020
122 pages
E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020
US$ 3,500.00
E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020 SUMMARY E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6....
February 2020
101 pages
